Skip to main content
Caplight Logo









Colossal

Colossal

Private
Austin, TexasHealthcare & Life Scienceshttps://www.colossal.com

Last Round

Series C

Extension

Sep 17, 2025

Est. Valuation

$10.32B

Total Funding Raised

$545M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Colossal Laboratories & Biosciences is a bioscience and genetic engineering company dedicated to developing innovative technologies aimed at advancing genomics, including species de-extinction and ecosystem restoration through the application of CRISPR technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Data as a Service

AI Layer

Application

Keywords

de-extinctiongenetic engineeringspecies resurrectionmammoth de-extinctionCRISPRecosystem restorationbiotechnologybiotechrewildingsynthetic biologysynbiokeystone speciesconservation technologyanimal cloningadvanced reproductive technologiescomputational biologygenomics softwarebiodiversity credits

Price History

Caplight MarketPrice™ estimate for Colossal, published with a 90-day delay.

Delayed data

Caplight MarketPrice™

$8.37

per share, as of June 2026

-61.2%

1-year change

The most recent months of MarketPrice™ are available to Caplight clients.

Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Colossal Comparables

Compare Colossal with similar companies based on industry and business-model similarity.

Colossal comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Revive & Restore
71%
Ginkgo Bioworks
61%
Los Angeles Project
56%

Colossal Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 17, 2025
Series CJan 15, 2025
Series BJan 31, 2023
GrantOct 5, 2022
Series AMar 9, 2022
Seed
Sep 13, 2021

Secondary Market Activity

Bids, offers, and trades by month

Data table
OperationDatePriceSizeShare ClassStructure
OFFER
BID

Key People

Founding team and executive leadership

Kent Wakeford

Co-Founder COO Advisor

Founding Team

Ben Lamm

Founder and CEO

Founding Team

Sam Singer

Chief Financial Officer

Executive Team

Adam Milne

Chief Operating Officer, Executive Advisory Board

Executive Team

Colossal Investors

Notable investors and investment history

Colossal investors
InvestorRounds
TWG GlobalSeries C
S32Series A
Breyer CapitalSeries C, Series B, Series A, Seed
Global Space VenturesSeed
Untamed PlanetSeries A
US Innovative Technology FundSeries B
Builders VCSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 30, 2026

    Partnered with Endangered Wildlife Trust for bluebuck rewilding.

  • Apr 21, 2026

    Won a gold Edison Award for mammalian cloning method.

Recent news

Latest coverage and updates

  • is_developingSep 27, 2026

    Colossal is developing cold-adapted, mammoth-like elephant on Sep 27th '26.

  • is_developingSep 17, 2026

    Colossal is developing regulatory-compliant rewilding roadmap for potential habitat restoration.

  • partners_withSep 17, 2026

    Colossal partners with Re:wild.

  • attends_eventSep 14, 2026

    Colossal will attend event TechCrunch Disrupt 2026 on Oct 1st '26.

  • partners_withAug 24, 2026

    Colossal partners with Paramount Group.

Colossal Filings

Explore SEC and related filing metadata, where available.

Colossal filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Appears On

Curated lists and screens where this company is featured.

Frequently Asked Questions

Common questions about Colossal's valuation, stock price, and market status.

Is Colossal a public or private company?

Colossal is a private company.

What is the current stock price of Colossal?

Colossal is a private company with no public stock price. Caplight tracks Colossal's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Colossal worth (valuation)?

Colossal's valuation is estimated at $10.3B based on funding round data.

Can I buy Colossal stock?

Colossal shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Colossal's last funding round?

Colossal's most recent funding round was Series C Extension on September 17, 2025.

Who are the main investors in Colossal?

Key investors in Colossal include TWG Global, Breyer Capital, US Innovative Technology Fund, At One Ventures, Tull Investment.

Will Colossal IPO soon?

No public IPO plans have been announced for Colossal.

How can I track Colossal secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Colossal's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAustin, Texas
Employee Range236
Year Founded2021
Last FundingSep 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?